
Opko Health (($OPK)) has held its Q3 earnings call. Read on for the main highlights of the call. OPKO Health Earnings Call Highlights LabCorp Sale and Pipeline Progress OPKO Health’s
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| OPK | Opko Health | 1.63 | 0.39 | 31.25% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.63 | +31.25% |

Opko Health (($OPK)) has held its Q3 earnings call. Read on for the main highlights of the call. OPKO Health Earnings Call Highlights LabCorp Sale and Pipeline Progress OPKO Health’s

Reports Q3 revenue $65.4M vs. $56.4M last year. The company said, “Following the Board of Directors’ September 30, 2026 approval of a plan to sell substantially all remaining BioReference diagnostic

The company said, “In light of the pending transaction with Labcorp, OPKO has withdrawn its previously issued guidance for services revenue and total costs and expenses due to uncertainty regarding

The company said, “In light of the pending transaction with Labcorp, OPKO has withdrawn its previously issued guidance for services revenue and total costs and expenses due to uncertainty regarding

Opko Health (OPK) is scheduled to report 3rd quarter earnings on 11/04/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Opko Health to post earnings of -$0.07

Analysts are intrested in these 5 stocks: ( ($OPK) ). Here is a breakdown of their recent ratings and the rationale behind them. Opko Health is suddenly back on analysts’

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Opko Health (OPK) to $4 from $3 and keeps an Overweight rating on the shares. The firm notes the

Barrington upgraded Opko Health (OPK) to Outperform from Market Perform with a $2.25 price target after the company entered into an agreement to divest its remaining BioReference Health assets to

Opko Health ( ($OPK) ) just unveiled an announcement. On October 14, 2026, OPKO Health and BioReference Health agreed to sell key assets of BioReference’s clinical and anatomic pathology laboratory

The major averages were mixed near noon as concerns around tech firms overspending on AI are mounting, leading to underperformance for the Nasdaq. Meanwhile, the producer price index rose 1.3%
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $1.25B | $-0.06 | $67.58M | -0.01 | -8.70 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.